$PTPI News

Last published 1y ago

1y agoPTPIPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionACCESS NewswireNEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. , a company focused on expanding consumer access to medication through over the
1y agoPTPIPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsACCESS NewswireThe Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. , a company focused on
1y agoPTPIPetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperACCESS NewswireWith more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros
1y agoPTPIPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformACCESS NewswireCompany continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros Pharmaceuticals,
1y agoPTPIPetros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC SwitchesACCESS NewswireLicensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again initiative NEW
1y agoPTPIPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsACCESS NewswireCompany's AI and Big Data technology positioned to drive strong industry collaborationCompany also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmaceuticals, Inc.
1y agoPTPIPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsACCESS NewswireCompany to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter NEW YORK, NY /
1y agoPTPIPetros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyACCESS NewswireProprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals, Inc.
1y agoPTPIPetros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsACCESS NewswireNEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. , a company focused on expanding consumer access to medication through
1y agoPTPIPetros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final RulesACCESS NewswireProprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc.
1y agoPTPIPetros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment"ACCESS NewswireCompany positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals, Inc.
1y agoPTPIProprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annuallyACCESS NewswireWorking to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE /
2y agoPTPIPetros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)ACCESS NewswireCompany is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc.
2y agoPTPIPetros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. , a company focused on expanding consumer access to medication through over-the- counter drug development
2y agoPTPIPetros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)ACCESS NewswireUtilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create
2y agoPTPIPetros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical SignificanceACCESS NewswireVital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros
2y agoPTPIPetros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC SwitchACCESS NewswireStudy paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc.
2y agoPTPIPetros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRAACCESS NewswireTeam composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDANEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros Pharmaceuticals,
2y agoME PTPIPetros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMeACCESS NewswireLemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity [1]Please see Important
2y agoME PTPILemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsGlobeNewswireSUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s
2y agoPTPIPetros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid HealthACCESS NewswireCollaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patientsNEW YORK, NY / ACCESSWIRE / April 23, 2024 /
2y agoPTPIPetros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)ACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. , a company focused on expanding
2y agoPTPIPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderACCESS NewswireAI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. , a
2y agoPTPIPetros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC SwitchACCESS NewswireFDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. , a company
2y agoPTPIPetros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC SwitchACCESS NewswireOver 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to
2y agoPTPIPetros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC StatusACCESS NewswireHuman Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approvalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. , a
2y agoPTPIPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderACCESS NewswireIdea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. , a
2y agoPTPIPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderACCESS NewswireIdea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc. , a company
3y agoPTPIPetros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)ACCESS NewswireNew AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction medication available OTCPetros in discussions with third-party
3y agoPTPIFollowing Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAACCESS NewswireImportant step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. , a
3y agoPTPIPetros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelACCESS NewswireCompany well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. , a company focused on expanding
3y agoPTPIPetros Pharmaceuticals to Present at the LD Micro Main Event XVIACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. , a company focused on expanding consumer access to medication through over the counter pathway, announces today that Fady
3y agoPTPIPetros Pharmaceuticals Provides Letter to ShareholdersACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. , a company focused on expanding consumer access to medication through over the counter pathway provides the below Letter
3y agoPTPIPetros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. , a pioneer in expanding consumer access to medication through over the counter pathways, announces today that Fady Boctor,
3y agoPTPIPetros Pharmaceuticals Announces Capital Raise of $15 MillionACCESS NewswireProvides Update on Progress Toward Over the Counter Development of STENDRANEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. ("Petros" or "the
3y agoOBLG PMCB PTPI SNPX+1Oblong Appoints Two New Directors to its BoardBusiness WireJonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new
4y agoPTPIInternationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of TherapyACCESS NewswireData Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According to the IIEF-EF Score NEW YORK, NY / ACCESSWIRE / Septe
4y agoAYRO CLAR DD HD+8The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company's Board of DirectorsBusiness WireDelivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong
4y agoPTPIPetros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022ACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2022. High
4y agoPTPIPetros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per shareGlobeNewswirePetros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company's healthcare platform Petros Pharmaceuticals common shareholders will receive $3.25 per share in cash CHICAGO, July 28, 2022 (GL
4y agoPTPIPetros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew PinskyGlobeNewswireNEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a compensated collaboration agreement with physician Dr. Drew Pinsky ("Dr.
4y agoPTPIPetros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the first quarter ended March 31, 2022.
4y agoPTPIPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the USGlobeNewswireNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel, pa
4y agoPTPIPetros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022GlobeNewswireNEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet M
4y agoPTPIPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor TechnologyGlobeNewswireNEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ((Petros, NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces it has entered into a Sponsored Research Agreement (SRA) and an Option Agreement with
4y agoPTPIPetros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)GlobeNewswireNEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today provides positive results from its over-the-counter (OTC) draft label compre
4y agoPTPIPetros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate HighlightsGlobeNewswireNEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021.
4y agoPTPIPetros Pharmaceuticals to Present at the Q1 Investor Summit ConferenceGlobeNewswireNEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at t
4y agoPTPIPetros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's HealthPR NewswireNEW YORK, Feb. 1, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement with celebrity physician Dr. Drew Pinsky ("Dr. Drew")
4y agoPTPIPetros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United StatesPR NewswireNEW YORK, Jan. 24, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces it has partnered with a leading Contract Development and Manufacturing Or